2.61 0.00 (0.00%)
After hours: 5:10PM EDT
|Bid||2.39 x 2200|
|Ask||2.78 x 3200|
|Day's Range||2.59 - 2.68|
|52 Week Range||2.02 - 5.70|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The gene-sequencing company received plenty of orders for its Sequel systems in the first quarter, but customers weren't ready for most of them.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks ( Stocks hitting 52-week highs on May 2 ) CASI Pharmaceuticals Inc (NASDAQ: CASI ) Eleven Biotherapeutics ...
The Menlo Park, California-based company said it had a loss of 20 cents per share. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pacific Biosciences of California Inc (NASDAQ:PACB) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.
Gainers Kadmon Holdings Inc (NYSE: KDMN ) shares are up 14 percent after announcing positive topline results from a Phase 2 study of KDO25. Vipshop Holdings Ltd – ADR (NYSE: VIPS ) shares are up 10 percent ...
Pacific Biosciences' (PACB) consumable revenue platform proves a vital growth-driver in Q4. Sales momentum in China remains robust.
The gene-sequencing company didn't have much good news from the fourth quarter, but better days could be ahead.
The Menlo Park, California-based company said it had a loss of 18 cents per share. The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
Pacific Biosciences (PACB) needs investors to pay close attention to the stock based on moves in the options market lately.
Another big purchase order for the genome sequencing equipment manufacturer ahead of its full-year 2017 earnings report is just what investors wanted to see.
Pacific Biosciences (PACB) faces cutthroat competition in the niche space. Also, sluggishness in the European markets is a concern.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Pacific Biosciences of California, Inc. Here are 5 ETFs with the largest exposure to PACB-US. Comparing the performance and risk of Pacific Biosciences of California, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns ... Read more (Read more...)